CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its initial public offering of 12,176,471 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,588,235 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Beam Therapeutics from the offerin
IPO
via https://www.AiUpNow.com
February 11, 2020 at 07:46AM by , Khareem Sudlow
What is A.I. Up to Now?
Blogs For Gadget Lovers. Have A Great Business Idea And You're Ready To Build Your Future, But Don't Know Where To Start? Let AiUpNow Guide You.
Trending
-
#SeoTips Housecall Pro, a leading software platform for over 45,000 home service companies, has launched new features and enhancements desig...
-
#SeoTips Investor Wesley Chan has shown a knack for making very early investments into multi-billion-dollar unicorns, such as Plaid, Gusto, ...
-
#SeoTips When digital marketing and eCommerce exploded into the retail market, a considerable amount of the conversation revolved around B2C...
